Entospletinib (ENTO) in Combination with Cytarabine (Ara-C) and Daunorubicin (DNR) in Newly Diagnosed (ND) Adult Patients with NPM1-Mutated and FLT3-ITD Wild-Type Acute Myeloid Leukemia (AML) Is Associated with Good Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2022-11, Vol.140 (Supplement 1), p.6200-6203
Hauptverfasser:	Borate, Uma, Li, Rui, Huang, Ying, Swords, Ronan T., Traer, Elie, Stein, Eytan, Foran, James M., Baer, Maria R., Duong, Vu H., Stock, Wendy, Odenike, Olatoyosi, Patel, Prapti, Collins, Robert H., Madanat, Yazan F., Kovacsovics, Tibor, Deininger, Michael W., Smith, Catherine, Olin, Rebecca L., Arellano, Martha L., Blum, William G., Schiller, Gary J., Lin, Tara L., Foster, Matthew C., Boyiadzis, Michael M., Redner, Robert L., Al-Mansour, Zeina, Curran, Emily K, Heerema, Nyla A., Gana, Theophilus J, Martycz, Molly, Rosenberg, Leonard, Marcus, Sonja, Yocum, Ashley O., Chen, Timothy, Stefanos, Mona, Druggan, Franchesca, Burd, Amy, Levine, Ross L., Druker, Brian J., Byrd, John C., Mims, Alice S.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!